From Policy To Practice: PBM Reform, TrumpRx, And Global Drug Development

By Ana Amaris, MD, MPH, Director, Health Policy Initiatives, ISPOR, Lawrenceville, NJ, USA

PBM reform and the launch of new pricing platforms are reshaping how medicines are priced, accessed, and evaluated across markets. Recent policy developments emphasize greater transparency in payment flows, heightened regulatory expectations, and evolving contracting standards intended to reduce opaque incentives and improve affordability.

The introduction of a federal drug‑pricing portal — built to display discounted cash prices negotiated under international reference‑based models — adds another layer of disruption by bypassing traditional intermediaries and redirecting cost comparisons directly to consumers. Early agreements signal a shift toward more open pricing structures, though experts caution that savings may vary widely depending on coverage status and therapeutic category.

At the global level, responses to U.S. pricing reforms include concerns about delayed launches, shifted investment strategies, and downstream effects on research priorities. These changes collectively signal a transition period in which policy, market incentives, and cross‑border regulatory environments intersect to influence future drug development and accessibility.